Italian laser technology group making medical/aesthetic lasers, industrial cutting/marking lasers, and lasers for art restoration.
Italian laser technology group making medical/aesthetic lasers, industrial cutting/marking lasers, and lasers for art restoration.
Medical and aesthetic lasers, sold to clinics and distributors worldwide, are the larger part of sales, with industrial cutting and marking lasers following the manufacturing cycle. The group has grown by building up many small specialist subsidiaries.
In one line: A diversified Italian laser maker, like a smaller Coherent.
Moat: narrow (IP / patents, process know-how). Proprietary laser source technology and decades of niche application know-how.
Headquarters: Calenzano, Italy · Founded: 1981 · Employees: 1,412
Size El.En (ELN.MI) is an Italy Health Care company (Medical Specialties) with a market value of $1.46B, the 68th largest of 121 Italy companies the cockpit tracks. Shares closed at €16.55 on 18 Nov 2026.
Performance Over six months the shares gained 11.1%, against -7.0% for the median peer and +3.1% for the Italy market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median +13.8%); the operating margin is 15.3% (peer median 6.8%).
Valuation It trades at 22.0× forward earnings against a peer median of 27.0× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.3 points above its cost of capital (11.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €552M | €591M | €566M | €576M | €674M |
| Revenue growth | — | +4% | -2% | -14% | — |
| Gross profit | €147M | €142M | €135M | €138M | €143M |
| EBITDA | €94.8M | €84.8M | €84.4M | €85.5M | €87.2M |
| Net income | €51.6M | €43.4M | €51.6M | €48.2M | €55.1M |
| Free cash flow | €79.7M | €60.1M | €75.0M | -€323,870 | -€15.3M |
| Capital expenditure | €12.9M | €11.6M | €9.46M | €13.7M | €18.4M |
| Total debt | n/a | €38.1M | €46.7M | €73.6M | €69.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| El.En ELN.MI | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% |
| IPG Photonics IPGP | $2.80B | -46% | +15% | 5% | 32.4× | 25.5% |
| Lumibird LBIRD.PA | $588M | -5% | +8% | 11% | 27.5× | 19.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ELN.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.3% | -0.9% | 5th highest of 21 |
| 6-month return | +11.1% | -7.0% | 6th highest of 21 |
| Distance from 52-week high | -6.2% | -28.4% | highest of 21 |
| Revenue growth (TTM) | +2.5% | +13.8% | 6th lowest of 21 |
| Operating margin | 15.3% | 6.8% | 7th highest of 21 |
| Forward P/E | 22.0× | 27.0× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 10.7% | 18.4% | 6th least demanding of 15 |
| Growth delivered (Del g) | +7.7% | +17.4% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +3.0 pp | -6.8 pp | 5th most demanding of 15 |
| ROIC minus cost of capital | +11.3 pp | -1.1 pp | 4th highest of 21 |
| EV / EBITDA | 12.3× | 15.7× | 4th cheapest of 8 |
| Net debt / EBITDA | -1.9× | -0.4× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |